SEC Form 4 · accession 0001562180-19-000071
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Sandor
Officer — Chief Medical Officer
Period of report
Dec 27, 2018
Accepted (ET)
Jan 2, 2019 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 27, 2018 | S | 6,268 | $14.0541 | D | 228,998 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $14.00 to $14.25. Details of actual prices for shares sold are available from the Issuer upon request.